Arcus Biosciences (RCUS) Receives News Sentiment Rating of 0.09
News articles about Arcus Biosciences (NYSE:RCUS) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arcus Biosciences earned a news impact score of 0.09 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.8280673006712 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Separately, Zacks Investment Research raised Arcus Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, July 11th.
RCUS stock opened at $12.85 on Monday. Arcus Biosciences has a 52 week low of $10.80 and a 52 week high of $22.10.
In related news, CEO Terry J. Rosen purchased 18,607 shares of the stock in a transaction that occurred on Tuesday, August 28th. The stock was purchased at an average cost of $15.07 per share, for a total transaction of $280,407.49. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Terry J. Rosen purchased 28,401 shares of the stock in a transaction that occurred on Thursday, August 16th. The stock was bought at an average price of $12.64 per share, with a total value of $358,988.64. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 85,117 shares of company stock valued at $1,118,707.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.
Read More: What is a Tariff?
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.